Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HTR7 | P34969 | 1/20 | 0.31 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.31 |
| ▸ | RORC | P51449 | 1/20 | 0.31 |
| ▸ | CTSL | P07711 | 1/20 | 0.30 |
| ▸ | CTSB | P07858 | 1/20 | 0.30 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20907500 | 1.00 | ALDH1A1 (0.32) | ALDH1A1KDM4EHTR7ALKRORC | |
| Hydrochloric Acid SCHEMBL22555786 | 0.99 | ALDH1A1 (0.31) | ALDH1A1KDM4EHTR7ALKRORC | |
| SCHEMBL22567492 | 0.87 | — | — | |
| SCHEMBL20898311 | 0.81 | KDM4E (0.35) | ALDH1A1KDM4ECTSLCTSBCTSS | |
| SCHEMBL22567429 | 0.81 | KDM4E (0.35) | ALDH1A1KDM4ECTSLCTSBCTSS | |
| SCHEMBL20907252 | 0.81 | KDM4E (0.35) | ALDH1A1KDM4ECTSLCTSBCTSS | |
| SCHEMBL24208967 | 0.80 | ALDH1A1 (0.31) | ALDH1A1KDM4ERORC | |
| SCHEMBL22015103 | 0.80 | ALDH1A1 (0.31) | ALDH1A1KDM4ERORC | |
| SCHEMBL24209224 | 0.80 | ALDH1A1 (0.31) | ALDH1A1KDM4ERORC | |
| SCHEMBL22015375 | 0.80 | ALDH1A1 (0.31) | ALDH1A1KDM4ERORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12060360-B2 | Lysyl oxidase inhibitors | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2024-08-13 | — | — | US | disclosed |
| CN-111212836-B | Lysyl oxidase inhibitors | 癌症研究所：皇家癌症医院 | 2023-12-15 | — | — | CN | disclosed |
| US-20220289757-A1 | LYSYL OXIDASE INHIBITORS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2022-09-15 | — | — | US | disclosed |
| US-11325915-B2 | Lysyl oxidase inhibitors | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2022-05-10 | — | — | US | disclosed |
| US-11325915-B2 | Lysyl oxidase inhibitors | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2022-05-10 | — | — | US | disclosed |
| US-20200331922-A1 | LYSYL OXIDASE INHIBITORS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2020-10-22 | — | — | US | disclosed |
| US-20200331922-A1 | LYSYL OXIDASE INHIBITORS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2020-10-22 | — | — | US | disclosed |
| EP-3694857-A1 | LYSYL OXIDASE INHIBITORS | The Institute of Cancer Research: Royal Cancer Hospital (GB) | 2020-08-19 | — | — | EP | disclosed |
| WO-2019073251-A1 | LYSYL OXIDASE INHIBITORS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2019-04-18 | — | — | WO | disclosed |
| WO-2019073251-A1 | LYSYL OXIDASE INHIBITORS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2019-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331922-A1 | LYSYL OXIDASE INHIBITORS | LOXL1, LOXL2, LOXL3 | ALDH1A1 1199/4885KDM4E 974/4885HTR7 3182/4885 |
| US-12060360-B2 | Lysyl oxidase inhibitors | LOXL1, LOXL2, LOXL3 | ALDH1A1 1199/4885KDM4E 974/4885HTR7 3182/4885 |
| US-20220289757-A1 | LYSYL OXIDASE INHIBITORS | LOXL1, LOXL2, LOXL3 | ALDH1A1 1199/4885KDM4E 974/4885HTR7 3182/4885 |
| US-11325915-B2 | Lysyl oxidase inhibitors | LOXL1, LOXL2, LOXL3 | ALDH1A1 1199/4885KDM4E 974/4885HTR7 3182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.